In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
 Nazzareno Galie
Speaker
Nazzareno Galie
Nazzareno Galie Nazzareno Galie

Alma Mater Studiorum, University of Bologna, Bologna (Italy)

Specialities : Pulmonary Circulation-Pulmonary Embolism-Right Heart Failure , Pharmacology and Pharmacotherapy, Chronic Heart Failure

Nazzareno Galiè (NG) graduated MD cum laude at the Alma Mater Studiorum University of Bologna (UNIBO) and attended the Postgraduate Specialization Schools of Cardiology and of Sports Medicine at UNIBO. NG is Full Professor of Cardiology at the Department of Experimental, Diagnostic and Specialty Medicine (DIMES) of the UNIBO. He is also Director of the Post-Graduate Specialization School of Cardiology at the DIMES-UNIBO and Director of the International Master Degree in Pulmonary Vascular Diseases of the DIMES-UNIBO (160 Graduates from 34 countries). NG is Head of the Cardiology Unit at the Cardio-Thoracic-Vascular Department of the Bologna Sant’Orsola University Hospital. NG has authored 264 cited publications on heart failure, pulmonary thromboembolic disease and pulmonary hypertension. The SCOPUS H-index is 77. NG has been included in the Thomson Reuters Highly Cited Researchers list in 2014 and 2016 and in the Clarivate Analytics Highly Cited Researchers list in 2017, 2018 e 2019.

33 presentations from this speaker

Achieving best long-term outcomes in PAH: How to choose the right treatments and when to start them

Event : ESC Congress 2020

  • Session : Looking PHorward to improving long-term outcomes in PAH
  • Speaker : N Galie (Bologna,IT)
  • Sponsored by Janssen Pharmaceutica NV

2019 Acute Pulmonary Embolism.

Event : ESC Congress 2019

  • Session : Congress Condensed - 2019 Clinical Practice Guidelines
  • Speaker : N Galie (Bologna,IT)

Closing remarks

Event : ESC Congress 2019

  • Session : Pulmonary arterial hypertension – The importance of assessing risk in treatment and management to delay disease progression
  • Speaker : N Galie (Bologna,IT)
  • Sponsored by Actelion Pharmaceuticals Ltd

Panel discussion - Pulmonary arterial hypertension

Event : ESC Congress 2019

  • Session : Pulmonary arterial hypertension – The importance of assessing risk in treatment and management to delay disease progression
  • Speaker : N Galie (Bologna,IT), M Humbert (Le Kremlin-Bicetre,FR)
  • Sponsored by Actelion Pharmaceuticals Ltd

Diagnosis and treatment challenges – Get it right from the start.

Event : ESC Congress 2018

  • Session : Achieve more in pulmonary arterial hypertension – Translating insights into patient benefits, Volume 1
  • Speaker : N Galie (Bologna,IT)
  • Sponsored by Actelion Pharmaceuticals Ltd

Long-term survival and safety with selexipag in patients with pulmonary arterial hypertension: results from the GRIPHON study and its open-label extension

Event : ESC Congress 2018

  • Session : Pulmonary hypertension: progress in management, impact on outcomes
  • Speaker : N Galie (Bologna,IT)

Panel discussion - Achieve more in pulmonary arterial hypertension – Translating insights into patient benefits, Volume 1

Event : ESC Congress 2018

  • Session : Achieve more in pulmonary arterial hypertension – Translating insights into patient benefits, Volume 1
  • Speaker : MM Hoeper (Hannover,DE), IM Lang (Vienna,AT), N Galie (Bologna,IT), JL Vachiery (Brussels,BE)
  • Sponsored by Actelion Pharmaceuticals Ltd

Closing remarks - The cardiologists' perspective on pulmonary hypertension.

Event : ESC Congress 2017

  • Session : The cardiologists' perspective on pulmonary hypertension - An interactive session
  • Speaker : N Galie (Bologna,IT)
  • Sponsored by MSD

Controlling disease progression – Is there still a place for monotherapy?

Event : ESC Congress 2017

  • Session : PAH – Timely and effective decisions in clinical practice
  • Speaker : N Galie (Bologna,IT)
  • Sponsored by Actelion Pharmaceuticals Ltd

Final remarks - PAH – Triple combination in a timely manner.

Event : ESC Congress 2017

  • Session : PAH – Triple combination in a timely manner
  • Speaker : N Galie (Bologna,IT)
  • Sponsored by Actelion Pharmaceuticals Ltd

Why pulmonary hypertension is important to cardiologists?

Event : ESC Congress 2017

  • Session : The cardiologists' perspective on pulmonary hypertension - An interactive session
  • Speaker : N Galie (Bologna,IT)
  • Sponsored by MSD

A patient with pulmonary arterial hypertension and cardiovascular risk factors - What do the Guidelines say?

Event : ESC Congress 2016

  • Session : Pulmonary hypertension in the elderly: do the Guidelines always help?
  • Speaker : N Galie (Bologna,IT)

Dual oral combination – Why it is so relevant.

Event : ESC Congress 2016

  • Session : Therapies and strategies – Stay ahead in pulmonary arterial hypertension (Volume 1)
  • Speaker : N Galie (Bologna,IT)
  • Sponsored by Actelion Pharmaceuticals Ltd

Initial versus sequential combination pharmacotherapy for PAH

Event : ESC Congress 2016

  • Session : Hot topics in pulmonary hypertension
  • Speaker : N Galie (Bologna,IT)

Panel discussion - Therapies and strategies – Stay ahead in pulmonary arterial hypertension (Volume 2).

Event : ESC Congress 2016

  • Session : Therapies and strategies – Stay ahead in pulmonary arterial hypertension (Volume 2)
  • Speaker : N Galie (Bologna,IT)
  • Sponsored by Actelion Pharmaceuticals Ltd

ESC/ERS pulmonary hypertension - Part 1

Event : ESC Congress 2015

  • Session : ESC Guidelines - Overview
  • Speaker : N Galie (Bologna,IT)

PAH management - Improving patient outcomes.

Event : ESC Congress 2015

  • Session : The patient-centric approach to pulmonary arterial hypertension management
  • Speaker : N Galie (Bologna,IT)
  • Sponsored by Actelion Pharmaceuticals Ltd

Pulmonary hypertension

Event : ESC Congress 2015

  • Session : Meet The Guidelines Task Force I - Ventricular Arrhythmias & Sudden Cardiac Death, Pulmonary Hypertension
  • Speaker : N Galie (Bologna,IT)

Changes in treatment strategies?

Event : ESC Congress 2014

  • Session : Should we amend the current pulmonary hypertension guidelines?
  • Speaker : N Galie (Bologna,IT)

How patients will take advantage of the completed and ongoing trials?

Event : ESC Congress 2014

  • Session : What is the impact of new drugs for treatment of pulmonary arterial hypertension patients?
  • Speaker : N Galie (Bologna,IT)

Initiating pulmonary arterial hypertension-specific therapy – Supportive evidence.

Event : ESC Congress 2014

  • Session : New horizons in pulmonary arterial hypertension – Addressing treatment initiation
  • Speaker : N Galie (Bologna,IT)
  • Sponsored by Actelion Pharmaceuticals Ltd

Panel discussion - New horizons in PAH.

Event : ESC Congress 2014

  • Session : New horizons in pulmonary arterial hypertension – Addressing treatment initiation
  • Speaker : N Galie (Bologna,IT), M Humbert (Le Kremlin-Bicetre,FR), S Rosenkranz (Koln,DE)
  • Sponsored by Actelion Pharmaceuticals Ltd

Presentation 1.

Event : ESC Congress 2014

  • Session : From treatment initiation to combination therapy
  • Speaker : N Galie (Bologna,IT)
  • Sponsored by Actelion Pharmaceuticals Ltd

Pulmonary artery denervation for pulmonary arterial hypertension.

Event : ESC Congress 2014

  • Session : New interventional and surgical procedures in pulmonary vascular diseases
  • Speaker : N Galie (Bologna,IT)

Risk-adjusted therapeutic strategies.

Event : ESC Congress 2014

  • Session : ESC Guidelines on pulmonary embolism. What is new? What has changed?
  • Speaker : N Galie (Bologna,IT)

Macitentan in SERAPHIN – Redefining outcomes in pulmonary arterial hypertension.

Event : ESC Congress 2013

  • Session : A paradigm shift – The first long-term morbidity and mortality study in pulmonary arterial hypertension
  • Speaker : N Galie (Bologna,IT)
  • Sponsored by Actelion Pharmaceuticals Ltd

New drugs on the horizon.

Event : ESC Congress 2013

  • Session : Pulmonary arterial hypertension. Where are we now?
  • Speaker : N Galie (Bologna,IT)

Get your access to resources

Join now
  • 1ESC Professional Members – access all ESC Congress resources 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are